1 Hypertension and Diabetes Should we be SPRINTING or Reaching an ACCORD? Suzanne Oparil, MD Distinguished Professor of Medicine, Professor of Cell, Developmental and Integrative Biology Director, Vascular Biology and Hypertension Program of the Division of Cardiovascular Disease University of Alabama at Birmingham, Birmingham, Alabama Past President, American Heart Association (AHA) Past President, American Society of Hypertension (ASH) University of Rochester School of Medicine and Dentistry University of Rochester Diabetes Conference: Diabetes In and Out Rochester, New York March 12, 2016
2 Cardiovascular Mortality Rate per 10,000 Patient-Years Elevated SBP in Type 2 Diabetes Increases Cardiovascular Risk Elevated SBP increases risk of CV death almost twofold in diabetic vs nondiabetic patients Stamler J et al. Diabetes Care. 1993;16: SBP (mm Hg) Nondiabetic patients Diabetic patients < MRFIT
3 JAMA. 2014;311(5): doi: /jama Published online December 18,
4 The Most Important Clinical Questions in Hypertension Does evidence from RCTs of antihypertensive treatment support (or refute) 140/90 mm Hg as a treatment threshold or goal? Should the threshold or goal be lower or higher in persons with diabetes or CKD, the elderly or those with other co-morbidities or special characteristics? Is there RCT evidence that BP lowering treatment with a particular drug or drug class improves outcomes compared to any other drug/drug class? James PA, Oparil S, Carter BL, et al. JAMA 2014;311(5): doi: /jama
5 The Most Important Clinical Questions in Hypertension Does evidence from RCTs of antihypertensive treatment support (or refute) 140/90 mm Hg as a treatment threshold or goal? Should the threshold or goal be lower or higher in persons with diabetes or CKD, the elderly or those with other co-morbidities or special characteristics? Is there RCT evidence that BP lowering treatment with a particular drug or drug class improves outcomes compared to any other drug/drug class? James PA, Oparil S, Carter BL, et al. JAMA 2014;311(5): doi: /jama
7 Recommendation 5 In the population 18 years of age with diabetes, initiate pharmacologic treatment to lower BP at SBP 140 mm Hg or DBP 90 mm Hg and treat to a goal SBP <140 mm Hg and goal DBP <90 mm Hg. (Expert Opinion Grade E)
8 The Most Important Clinical Questions in Hypertension Does evidence from RCTs of antihypertensive treatment support (or refute) 140/90 mm Hg as a treatment threshold or goal? Should the threshold or goal be lower or higher in persons with diabetes or CKD, the elderly or those with other co-morbidities or special characteristics? Is there RCT evidence that BP lowering treatment with a particular drug or drug class improves outcomes compared to any other drug/drug class? James PA, Oparil S, Carter BL, et al. JAMA 2014;311(5): doi: /jama
9 Recommendation 6 In the general non-black population, including those with diabetes, initial antihypertensive treatment should include a thiazide-type diuretic, CCB, ACEI or ARB. Moderate Recommendation Grade B
10 Initial Combinations of Medications Diuretics β-blockers should be included in the regimen if there is a compelling indication for a β-blocker ACE inhibitors or ARBs* Calcium antagonists * Combining ACEI with ARB discouraged
12 Comprehensive Overview of Effects of BP-lowering in Patients with Diabetes Regardless of the Presence or Absence of Defined Hypertension Who should be offered therapy? What BP target(s) should be achieved? 40 trials of high quality (low risk of bias) 100,354 participants All-cause mortality + 4 macrovascular and 3 microvascular outcomes Emdin CA, et al. Blood pressure lowering in type 2 diabetes. JAMA. 313(6): , 2015.
13 Associations Between 10 mmhg Lower SBP and Mortality, Macrovascular and Microvascular Outcomes in Diabetic Patients Emdin CA, et al. Blood pressure lowering in type 2 diabetes. JAMA. 313(6): , 2015.
14 Associations Between 10 mmhg Lower SBP and CVD Outcomes Stratified by SBP at Entry MORTALITY 140 <140 Overall CARDIOVASCULAR DISEASE 140 <140 Overall CORONARY ARTERY DISEASE 140 <140 Overall STROKE 140 <140 Overall Emdin CA, et al. Blood pressure lowering in type 2 diabetes. JAMA. 313(6): , 2015.
15 Associations Between 10 mmhg Lower SBP and CVD Outcomes Stratified by SBP at Entry HEART FAILURE 140 <140 Overall RENAL FAILURE 140 <140 Overall RETINOPATHY 140 <140 Overall ALBUMINURIA 140 <140 Overall Emdin CA, et al. Blood pressure lowering in type 2 diabetes. JAMA. 313(6): , 2015.
16 Associations Between 10 mm Hg Lower SBP and Outcomes Stratified by Achieved SBP MORTALITY 130 < 130 Overall CARDIOVASCULAR DISEASE 130 < 130 Overall CORONARY ARTERY DISEASE 130 < 130 Overall STROKE 130 < 130 Overall Emdin CA, et al. Blood pressure lowering in type 2 diabetes. JAMA. 313(6): , 2015.
17 Associations Between 10 mm Hg Lower SBP and Outcomes Stratified by Achieved SBP HEART FAILURE 130 < 130 Overall RENAL FAILURE 130 < 130 Overall RETINOPATHY 130 < 130 Overall ALBUMINURIA 130 < 130 Overall Emdin CA, et al. Blood pressure lowering in type 2 diabetes. JAMA. 313(6): , 2015.
18 Associations of Each Class of Antihypertensive on Outcomes Compared With All Other Classes of Antihypertensives MORTALITY CCB ACE Diuretics Β-Blocker ARB CARDIOVASCULAR DISEASE CCB ACE Diuretics Β-Blocker ARB CORONARY HEART DISEASE CCB ACE Diuretics Β-Blocker ARB Emdin CA, et al. Blood pressure lowering in type 2 diabetes. JAMA. 313(6): , 2015.
19 Associations of Each Class of Antihypertensive on Outcomes Compared With All Other Classes of Antihypertensives STROKE CCB ACE Diuretics Β-Blocker ARB HEART FAILURE CCB ACE Diuretics Β-Blocker ARB Emdin CA, et al. Blood pressure lowering in type 2 diabetes. JAMA. 313(6): , 2015.
20 SUMMARY SBP reduction (10 mmhg) lowered risk of all-cause mortality, CVD and CHD events and stroke, as well as retinopathy and albuminuria, but not HF or renal failure in the diabetic population as a whole. SBP reduction lowered risk of mortality, CVD, CHD and HF only in those with baseline SBP 140 mm Hg. SBP reduction lowered risk of stroke and albuminuria in all participants, independent of baseline SBP. Reductions in mortality, CHD, CVD, HF and albuminuria were greater at achieved SBPs 130 mmhg than < 130 mmhg. Emdin CA, et al. Blood pressure lowering in type 2 diabetes. JAMA. 313(6): , 2015.
21 SUMMARY Reductions in stroke and albuminuria were similar in both achieved BP strata. All classes of BP-lowering medications had similar effects except Diuretics and possibly ARBs were more effective in preventing HF. CCBs were less effective in preventing HF and more effective in preventing stroke. BBs were less effective in preventing stroke. ARBs were more effective in preventing death (limited data). Emdin CA, et al. Blood pressure lowering in type 2 diabetes. JAMA. 313(6): , 2015.
22 RECOMMENDATIONS Among patients with type 2 diabetes, BP lowering was associated with reduction in mortality and other clinical outcomes in those with baseline BP 140 mmhg. These findings support the use of medications for BP lowering in these patients. For individuals at high risk of stroke, retinopathy, and progressive albuminuria (e.g., those with a history of cerebrovascular disease or mild nonproliferative diabetic retinopathy), beginning BP-lowering therapy at an initial SBP level below 140 mm Hg and treatment to a SBP level below 130 mm Hg should be considered. Emdin CA, et al. Blood pressure lowering in type 2 diabetes. JAMA. 313(6): , 2015.
23 RECOMMENDATIONS Individualized assessment of likely absolute benefits and risks is vital to shared decisionmaking between patients and clinicians. Emdin CA, et al. Blood pressure lowering in type 2 diabetes. JAMA. 313(6): , 2015.
24 Recent Recommendations for Antihypertensive Medications in Diabetes Group ESH/ESC (2013) ESC/EASD (2013) AHA/ACC/CDC Science Advisory (US) (2013) ADA ( ) ASH-ISH (2013) US JNC 8 Panel (2014) US VA/DoD (2014) Preferred Medications* All All ACEI or ARB, thiazide, BB, CCB ACEI or ARB ARB or ACEI thiazide-type diuretic, CCB, ACEI or ARB; Blacks: thiazide or CCB Thiazide-type diuretic * All guidelines recommend ACEI or ARB if proteinuria, some if any CKD
25 Cushman WC, Evans GW, Byington RP, et al, the Accord Study Group. N Engl J Med 362(17): , 2010.
26 ACCORD BP Study: Primary and Secondary Outcomes Patients with T2D and hypertension (N = 4733) Random assignment Intensive therapy: target SBP < 120 mm Hg Standard therapy: target SBP < 140 mm Hg 1 outcome: nonfatal MI, nonfatal stroke, death from CV causes Mean follow-up = 4.7 y Outcome Intensive Standard HR P-value SBP after 1 year (mmhg) NR NR 1 outcome (annual rate) Death from any cause (annual rate) Stroke (annual rate) AEs (rate) NR <.001 Cushman WC, Evans GW, Byington RP et.al, and Ismail-Beigi F. N.Engl.J.Med. 2010;362 :
27 ACCORD BP Trial: Systolic BP (mean + 95% CI) Mean # Meds Intensive: Standard: Average after 1 st year: Standard vs Intensive, Delta = 14.2 N RZ: SBP <120 vs <140 DBP for the same time interval averaged 70 & 64 mm Hg (Delta = 6 mm Hg) Cushman, et al. N Engl J Med. 2010;362:
28 Intensive Events (%/yr) Standard Events (%/yr) HR (95% CI) P Primary 208 (1.87) 237 (2.09) 0.88 ( ) 0.20 Total Mortality 150 (1.28) 144 (1.19) 1.07 ( ) 0.55 Cardiovascular Deaths 60 (0.52) 58 (0.49) 1.06 ( ) 0.74 Nonfatal MI 126 (1.13) 146 (1.28) 0.87 ( ) 0.25 Nonfatal Stroke 34 (0.30) 55 (0.47) 0.63 ( ) 0.03 Total Stroke 36 (0.32) 62 (0.53) 0.59 ( ) 0.01 Also examined Fatal/Nonfatal HF (HR=0.94, p=0.67), a composite of fatal coronary events, nonfatal MI and unstable angina (HR=0.94, p=0.50) and a composite of the primary outcome, revascularization and unstable angina (HR=0.95, p=0.40)
29 20 Primary Outcome Nonfatal MI, Nonfatal Stroke or CVD Death Patients with Events (%) HR = % CI ( ) Years Post-Randomization
30 Nonfatal Stroke Total Stroke Patients with Events (%) HR = % CI ( ) Patients with Events (%) HR = % CI ( ) Years Post-Randomization Years Post-Randomization
31 Intensive N (%) Standard N (%) Serious AE 77 (3.3) 30 (1.3) < Hypotension 17 (0.7) 1 (0.04) < Syncope 12 (0.5) 5 (0.2) 0.10 Bradycardia or Arrhythmia 12 (0.5) 3 (0.1) 0.02 Hyperkalemia 9 (0.4) 1 (0.04) 0.01 Renal Failure 5 (0.2) 1 (0.04) 0.12 egfr ever <30 ml/min/1.73m 2 99 (4.2) 52 (2.2) <0.001 Any Dialysis or ESRD 59 (2.5) 58 (2.4) 0.93 Dizziness on Standing 217 (44) 188 (40) 0.36 P Symptom experienced over past 30 days from HRQL sample of N=969 participants assessed at 12, 36, and 48 months post-randomization
32 Primary Outcome by Pre-defined Sub-groups Cushman WC-AHA Late Breaker Nov. 2015
33 Margolis, et al.diabetes Care 2014;37:
34 ACCORD BP Trial Conclusions The results provide no conclusive evidence that the intensive BP control strategy reduces combined CVD events in high risk patients with diabetes mellitus. However, the trial was unexpectedly underpowered (CI , rate 2%/yr). Therefore, ACCORD also does not conclusively prove that <120 mm Hg goal is not beneficial (equipoise).
35 Systolic Blood Pressure Intervention Trial (SPRINT) SPRINT Research Group, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood-Pressure Control, 373(22): , 2015.
36 Major Exclusion Criteria Stroke Diabetes mellitus Polycystic kidney disease Congestive heart failure (symptoms or EF < 35%) Proteinuria >1g/d CKD with egfr < 20 ml/min/1.73m 2 (MDRD) Adherence concerns
37 Decision to Stop BP Intervention On August 20 th, 2015, NHLBI Director accepted DSMB recommendation to inform SPRINT investigators and participants of CVD results Concurrently, decision made to stop BP intervention This presentation based on adjudicated events that occurred through August 20 th, 2015 Median follow-up = 3.26 years Data for some secondary non-cvd outcomes (e.g. dementia and cognitive impairment) being collected at close-out visit, and this process will be completed in Summer 2016
38 Cumulative Hazard for SPRINT Primary Outcome Hazard Ratio = 0.76 (95% CI: 0.64 to 0.89) Standard Intensive During Trial (median follow-up = 3.26 years) Include Number Needed NNT to Treat (NNT) to prevent a primary outcome in one participant = 61 Number of Participants SPRINT Study Research Group. Published online NEJM, Nov 9, 2015
39 Cumulative Hazard for All-cause Mortality Hazard Ratio = 0.73 (95% CI: 0.60 to 0.90) Standard Intensive During Trial (median follow-up = 3.26 years) Number Needed to Treat (NNT) to Prevent death in one participant = 90 Include NNT Number of Participants SPRINT Study Research Group. Published online NEJM, Nov 9, 2015
40 SPRINT Primary Outcome and Component Event Rates and Hazard Ratios Primary Outcome Intensive No. of Events Rate, %/year Standard No. of Events Rate, %/year HR (95% CI) (0.64, 0.89) P value < All MI (0.64, 1.09) Non-MI ACS (0.64, 1.55) All Stroke (0.63, 1.25) All HF (0.45, 0.84) CVD Death (0.38, 0.005
41 Serious Adverse Events* (SAE) During Follow-up All SAE reports Number (%) of Participants Intensive Standard HR (P Value) 1793 (38.3) 1736 (37.1) 1.04 (0.25) SAEs associated with Specific Conditions of Interest Hypotension 110 (2.4) 66 (1.4) 1.67 (0.001) Syncope 107 (2.3) 80 (1.7) 1.33 (0.05) Injurious fall 105 (2.2) 110 (2.3) 0.95 (0.71) Bradycardia 87 (1.9) 73 (1.6) 1.19 (0.28) Electrolyte abnormality 144 (3.1) 107 (2.3) 1.35 (0.02)
42 FAQs ABOUT SPRINT GENERALIZABILITY TO EXCLUDED POPULATIONS AGE < 50 years? Diabetes? Prior stroke? Heart failure? Secondary hypertension? Severe CKD (egfr < 20mL/min/1.73 m 2 or proteinuria)? Frail elderly? High CVD risk without hypertension? Lower CVD risk with hypertension?
43 Outcomes from SPRINT and ACCORD Trials and Combined Data from Both Trials. Perkovic V, Rodgers A. N Engl J Med DOI: /NEJMe
44 ACCORD vs SPRINT 1. SPRINT sample size was about twice that of ACCORD BP. 2. SPRINT participants were older (mean age 68 years) than ACCORD BP (mean age 62 years). 3. SPRINT included a cohort with CKD, but serum Cr >1.5 mg/dl was an exclusion in ACCORD BP. 4. The factorial design in ACCORD may have negatively affected the opportunity to test the effect of the BP intervention.
45 Strict interpretation of RCTs supports SBP goal of <150 mm Hg. Achieved SBP in ADVANCE and the standard group in ACCORD BP suggest <140 mm Hg may be a reasonable SBP goal (JNC 8 and most other current guidelines recommend this). A recent meta-analysis suggests <130 mm Hg. ACCORD benefit in the Standard Glycemia subgroup and SPRINT benefit in other high-risk groups support <120 mm Hg.
46 STANDARDS OF MEDICAL CARE IN DIABETES 2016 Diabetes Care 2016;39(Suppl. 1):S1 S108 DOI: /dc16-S011.
47 ADA Evidence Grading System for Clinical Practice Recommendations LEVEL OF EVIDENCE A DESCRIPTION Clear or supportive evidence from adequately powered well-conducted, generalizable, randomized controlled trials; Compelling nonexperimental evidence B C E Supportive evidence from well-conducted cohort studies or case-control study Supportive evidence from poorly controlled or uncontrolled studies; Conflicting evidence with the weight of evidence supporting the recommendation Expert consensus or clinical experience Diabetes Care 2016;39(Suppl. 1):S1 S108 DOI: /dc16-S011.
48 Goals ADA RECOMMENDATIONS Hypertension/BP Control People with diabetes and hypertension should be treated to a SBP goal of < 140 mmhg A Lower systolic targets, such as < 130 mmhg, may be appropriate for some, e.g., younger patients and higher-risk patients, if it can be achieved without undue treatment burden C Those with diabetes should be treated to a DBP < 90 mmhg A Lower diastolic targets, e.g., < 80 mmhg, may be appropriate for some, e.g., younger patients and higher-risk patients, if it can be achieved without undue treatment burden B Diabetes Care 2016;39(Suppl. 1):S60 S71 DOI: /dc16-S011. ADA. 8. Cardiovascular Disease and Risk Management. Diabetes Care
49 ADA RECOMMENDATIONS Hypertension/BP Control Treatment Patients with BP >120/80 mmhg should be advised on lifestyle changes to reduce BP B Patients with confirmed BP higher than 140/90 mmhg should, in addition to lifestyle therapy, have prompt initiation and timely subsequent titration of pharmacological therapy to achieve BP goals A Diabetes Care 2016;39(Suppl. 1):S1 S108 DOI: /dc16-S011.
50 *Treatment ADA RECOMMENDATIONS Hypertension/BP Control Pharmacological therapy for patients with diabetes and hypertension comprise a regimen that includes: either an ACE inhibitor or angiotensin receptor blocker B; if one class is not tolerated, substitute the other C Multiple drug therapy (two or more agents at maximal doses) generally required to achieve BP targets B *Inconsistent with JNC 8. Diabetes Care 2016;39(Suppl. 1):S1 S108 DOI: /dc16-S011.
51 Treatment ADA RECOMMENDATIONS Hypertension/BP Control If ACE inhibitors, ARBs, or diuretics are used, serum creatinine/egfr and potassium levels should be monitored E In pregnant patients with diabetes and chronic hypertension, BP target goals of /65 79 mmhg are suggested in interest of long-term maternal health and minimizing impaired fetal growth; ACE inhibitors, ARBs, contraindicated during pregnancy E Diabetes Care 2016;39(Suppl. 1):S1 S108 DOI: /dc16-S011.
52 Management of Hypertension in Diabetes Hypertension is present in >2/3 of patients with type 2 diabetes. Hypertension and diabetes confer a much enhanced risk of cardiovascular disease than either one alone. Clinical trial evidence suggests that BP < /85 mm Hg is a reasonable therapeutic goal in patients with type 2 diabetes mellitus. However, SPRINT + ACCORD suggest SBP <120 mm Hg may be considered. In patients with diabetes, a combination of a RAS-blocker and a thiazide-type diuretic might be the most reasonable initial antihypertensive regimen, although CCBs and CCB-ACEI combination are also effective.
53 BP Goals in People with Diabetes It is possible that there is an inherent difference in the CVD benefits of intensive SBP lowering in diabetic and non-diabetic adults. Because ACCORD BP was not definitive, it would be ethical to conduct another trial of intensive BP-lowering on major CVD outcomes in diabetics. Enrollment of a higher risk group (e.g., participants of older age and those with CKD) and enlarging the sample size would help to ensure adequate statistical power to answer this question. In the meantime, guideline committees and the medical community will have to decide whether the SPRINT results should be generalized to patients with hypertension and diabetes mellitus. Cushman, et al. Published online in Hypertension, Nov 9,2015.
Hypertension Guidelines: Lessons for Primary Care Paul A James MD Professor and Chair Department of Family Medicine University of Washington Disclaimer and Financial Disclosure I have no financial interests
New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of
JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation
Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, 2015 William C. Cushman, MD Professor, Preventive Medicine, Medicine, and Physiology University
HYPERTENSION: UPDATE 2018 From the Cardiologist point of view Richard C Padgett, MD I have no disclosures HYPERTENSION ALWAYS THE ELEPHANT IN THE EXAM ROOM BUT SOMETIMES IT CHARGES HTN IN US ~78 million
Diabetes and Hypertension William C. Cushman, MD, FAHA, FACP, FASH Chief, Preventive Medicine, Veterans Affairs Medical Center Professor, Preventive Medicine, Medicine, and Physiology University of Tennessee
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
Research Article JNC 8 versus JNC 7 Understanding the Evidences Anns Clara Joseph, Karthik MS, Sivasakthi R, Venkatanarayanan R, Sam Johnson Udaya Chander J* RVS College of Pharmaceutical Sciences, Coimbatore,
The New Hypertension Guidelines Joseph Saseen, PharmD Professor and Vice Chair, Department of Clinical Pharmacy University of Colorado Anschutz Medical Campus Disclosure Joseph Saseen reports no conflicts
T. Suithichaiyakul Cardiomed Chula The cardiovascular (CV) continuum: role of risk factors Endothelial Dysfunction Atherosclerosis and left ventricular hypertrophy Myocardial infarction & stroke Endothelial
Evolving Concepts on Hypertension: Implications of Three Guidelines (JNC 8 Panel, ESH/ESC, NICE/BSH) Sidney C. Smith, Jr. MD, FACC, FAHA, FESC Professor of Medicine/Cardiology University of North Carolina
Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT
Hypertension and the SPRINT Trial: Is Lower Better 8th Annual Orange County Symposium on Cardiovascular Disease Prevention Saturday, October 8, 2016 Keith C. Norris, MD, PhD, FASN Professor of Medicine,
9:45 :30am Hypertension Management: A Moving Target SPEAKER Karol Watson, MD, PhD, FACC Presenter Disclosure Information The following relationships exist related to this presentation: Karol E. Watson,
Hypertension in 2015: SPRINT-ing ahead of JNC-8 MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Conflits of interest? None Disclaimer The opinions contained herein are not to be considered
Managing Hypertension in Diabetes 2015 Sean Stewart, PharmD, BCPS, BCACP, CLS Internal Medicine Park Nicollet Clinic St Louis Park Case Scenario Mike M is a 59 year old man with type 2 diabetes managed
Blood Pressure Targets: Where are We Now? Diana Cao, PharmD, BCPS-AQ Cardiology Assistant Professor Department of Clinical & Administrative Sciences California Northstate University College of Pharmacy
The Latest Generation of Clinical Guidelines: HTN and HLD Dave Brackett Clinical Guideline Purpose Uniform approach Awareness of key details Diagnosis Treatment Monitoring Evidence based approach Inform
Hypertension Update Daniel Schwartz, MD Assistant Professor of Medicine Associate Medical Director of Heart Transplantation Temple University School of Medicine Disclosures I currently have no relationships
Long-Term Care Updates August 2015 By Darren Hein, PharmD Hypertension is a clinical condition in which the force of blood pushing on the arteries is higher than normal. This increases the risk for heart
Hypertension and Cardiovascular Disease Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic,
Implementation: Joint National Committee on High Blood Pressure JNC 8 Joel Handler, MD Kaiser Permanente Care Management Institute Hypertension Lead Southern California Permanente Group Objective & Outline
Treating Hypertension in Individuals with Diabetes Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any
ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE DISCLOSURES Editor-in-Chief- Nephrology- UpToDate- (Wolters Klewer) Richard J. Glassock, MD, MACP Geffen School of Medicine at UCLA 1 st Annual Internal
Masked Hypertension Why Should We Care? Dr. Peter J. Lin Director Primary Care Initiatives - Canadian Heart Research Centre PRESENTER DISCLOSURE Faculty: Dr. Peter Lin Relationships with commercial interests:
Treating Hypertension in 2018: What Makes the Most Sense Today? Daniel Blanchard, MD Professor of Medicine UC San Diego Cardiovascular Center La Jolla, California 1 2 Speaker Disclosures Consultant and/or
Richard Roetzheim, MD, MSPH is Professor and Chair, Department of Family Medicine at the University of South Florida Morsani College of Medicine. Dr. Roetzheim has considerable experience leading NIH funded
2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC 8) James W. Shaw, MD Memorial Lecture
HYPERTENSION TARGETS: WHAT DO WE DO NOW? MICHAEL LEFEVRE, MD, MSPH PROFESSOR AND VICE CHAIR DEPARTMENT OF FAMILY AND COMMUNITY MEDICINE UNIVERSITY OF MISSOURI 4/4/17 DISCLOSURE: MEMBER OF THE JNC 8 PANEL
SPRINT: Consequences for CKD patients 29 e Workshop Nierziekten Papendal 2018 December 12, 2018 MICHAEL ROCCO, MD, MSCE VARDAMAN M. BUCKALEW JR. PROFESSOR OF MEDICINE PROFESSOR OF PUBLIC HEALTH SCIENCES
1 U.S. Department of Health and Human Services National Institutes of Health Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker
Recent Hypertension Guidelines Lawrence J. Fine, MD, DrPH, FAHA Division of Cardiovascular Sciences NHLBI/NIH February 19, 2014 Disclosures: Member of Panel Appointed to the Eighth Joint National Committee
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant
Management of Lipid Disorders and Hypertension Management of Lipid Disorders and Hypertension: Implications of the New Guidelines Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine
Blood Pressure Treatment Goals Kenneth Izuora, MD, MBA, FACE Associate Professor UNLV School of Medicine November 18, 2017 Learning Objectives Discuss the recent studies on treating hypertension Review
Understanding the importance of blood pressure control An overview of new guidelines: How do they impact daily current management? Slides presented during CDMC in Almaty, Kazakhstan on Saturday April 12,
Managing Hypertension in 2016: Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine email@example.com
Hypertension 101 Jared Moore, MD, FACP Assistant Program Director, Internal Medicine Residency Clinical Assistant Professor of Internal Medicine Division of General Medicine The Ohio State University Wexner
HYPERTENSION MANAGEMENT IN ELDERLY POPULATIONS Michael J. Scalese, PharmD, BCPS, CACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 14, 2018 DISCLOSURE/CONFLICT OF INTEREST
Reframe the Paradigm of Hypertension treatment Focus on Diabetes Paola Atallah, MD Lecturer of Clinical Medicine SGUMC EDL monthly meeting October 25,2016 Overview Physiopathology of hypertension Classification
Hypertension Update 2016 AREEF ISHANI, MD MS CHIEF OF MEDICINE MINNEAPOLIS VA MEDICAL CENTER PROFESSOR OF MEDICINE UNIVERSITY OF MINNESOTA Case 1 What should be your BP goal for an elderly (> 75 yrs of
Diabetes and Hypertension M.Nakhjvani,M.D Tehran University of Medical Sciences 20-8-96 Hypertension Common DM comorbidity Prevalence depends on diabetes type, age, BMI, ethnicity Major risk factor for
MANAGING HYPERTENSION IN 2018 How Do We Work With Conflicting Data and Conflicting Guidelines? Disclosure No relevant financial relationships Robert B. Baron, MD MS Professor and Associate Dean UCSF School
Evaluation and Management of Hypertension in Women Vesna D. Garovic, M.D. Moscow, Russia, December 2016 2016 MFMER 3508058-1 Women are not small men There is nothing as powerful as an idea whose time has
New Clinical Trends in Geriatric Medicine April 8, 2016 Amanda Lathia, MD, MPhil Staff, Center for Geriatric Medicine Objectives Review current guidelines for blood pressure (BP) control in older adults
ALLHAT Antihypertensive Trial Results by Baseline Diabetic & Fasting Glucose Status 1 Introduction and Background Clinical trials have reported reduction in CV events with diuretics, CCBs, ACE inhibitors,
Hypertension Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute Hypertension 2017 Classification BP Category Systolic Diastolic Normal 120 and 80 Elevated
Predicting and changing the future for people with CKD I. David Weiner, M.D. Co-holder, C. Craig and Audrae Tisher Chair in Nephrology Professor of Medicine and Physiology and Functional Genomics University
Egyptian Hypertension Guidelines 2014 Egyptian Hypertension Guidelines Dalia R. ElRemissy, MD Lecturer of Cardiovascular Medicine Cairo University Why Egyptian Guidelines? Guidelines developed for rich
New Hypertension Guidelines: Why the change? Neil Brummond, M.D. Avera Medical Group Internal Medicine Sioux Falls, SD None Disclosures Objectives Understand trend in blood pressure clinical practice guidelines
Disclosures I have no current or past relationships with commercial entities I have received a speaker s fee from the Ontario Pharmacists Association for this learning activity Laura Tsang PharmD Sunnybrook
PHASE Safety Net Community Benefit Hypertension: 2016 Clinical Update Presented by: Joseph Young, MD Hypertension Clinical Lead Kaiser Permanente Northern California October 6, 2016 Dr. Joseph Young Hypertension
Management of Hypertension M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine Disturbing Trends in Hypertension HTN awareness, treatment and control rates are decreasing
Update in Hypertension Eliseo J. PérezP rez-stable MD Professor of Medicine DGIM, Department of Medicine UCSF 20 May 2008 Declaration of full disclosure: No conflict of interest (I have never been funded
Stockholm, 29 th August 2010 ESC Meeting Blood Pressure Targets in Diabetes Peter M Nilsson, MD, PhD Department of Clinical Sciences University Hospital, Malmö Sweden Studies on BP in DM2 ADVANCE RCT (Lancet
Friday General Session Update on Current Trends in Hypertension Management Shawna Nesbitt, MD Associate Dean, Minority Student Affairs Associate Professor, Department of Internal Medicine Office of Student
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
Supplementary Online Content James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report by the panel appointed to the Eighth Joint National
The earlier BP control the better cardiovascular outcome Jin Oh Na Cardiovascular center Korea University Medical College Index Introduction HOPE-3 Trial Sprint Study Summary Each 2 mmhg decrease in SBP
MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine firstname.lastname@example.org
MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine email@example.com
American College of Physicians Ohio/Air Force Chapters 2018 Scientific Meeting Columbus, OH October 5, 2018 What s In the New Hypertension Guidelines? Max C. Reif, MD, FACP Objectives: At the end of the
Hypertension JNC 8 (2014) Renewed: February 2018 Updated: February 2015 Comparison of Seventh Joint National Committee (JNC 7) vs. Eighth Joint National Committee (JNC 8) Hypertension Guidelines Methodology
Tread Carefully Because you Tread on my Nephrons Prescribing Hints in Renal Disease David WP Lappin,, MB PhD FRCPI Clinical Lecturer in Medicine and Consultant Nephrologist and General Physician, Merlin
Hypertension Management in Diabetic Patients Park, Chang G, MD, PhD Cardiovascular Center, Guro Hospital, Korea University Medical School Contents (Treatment of 2 Cases) Type 2 Diabetes Mellitus Hypertension
Lessons learned from AASK (African-American Study of Kidney Disease and Hypertension) Janice P. Lea, MD, MSc, FASN Professor of Medicine Chief Medical Director of Emory Dialysis ASH Clinical Specialist
1 ALLHAT Role of Diuretics in the Prevention of Heart Failure - The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial Davis BR, Piller LB, Cutler JA, et al. Circulation 2006.113:2201-2210.
Preventing and Treating High Blood Pressure: Finding the Right Balance of Integrative and Pharmacologic Approaches Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Blood Pressure
Page 1 of 20 Special Communication February 5, 2014 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National
HYPERTENSION: ARE WE GOING TOO LOW? George L. Bakris, M.D.,F.A.S.N.,F.A.S.H., F.A.H.A. Professor of Medicine Director, ASH Comprehensive Hypertension Center University of Chicago Medicine Chicago, IL USA
Hypertension Update 2009 New Drugs, New Goals, New Approaches, New Lessons from Clinical Trials Timothy C Fagan, MD, FACP Professor Emeritus University of Arizona New Drugs Direct Renin Inhibitors Endothelin
Unpacking Recent Hypertension Guidelines Lawrence J. Fine, MD, DrPH, FAHA Division of Cardiovascular Sciences NHLBI/NIH August 21, 2014 Disclosures: Member of Panel Appointed to the Eighth Joint National
Outcomes in Hypertensive Black and Nonblack Patients Treated with Chlorthalidone, Amlodipine, and Lisinopril* *Wright JT, Dunn JK, Cutler JA et al. JAMA 2005:293:1595-1608. 42,418 High-risk hypertensive
Hypertension Guidelines 2016 Michael A. Weber, MD Division of Cardiovascular Medicine State University of New York Downstate Medical Center Speaker Disclosures I disclose that I am a Consultant for: Ablative
Measure Up/Pressure Down Response to the Release of 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report from the Panel Members Appointed to the Eighth Joint National
Cardiovascular system DEBATE Go low or no? Managing blood pressure in primary care There is much debate as to whether intensive blood pressure management, i.e. aiming for a systolic blood pressure less
Balanced information for better care Don t let the pressure get to you: Current evidence-based goals for treating hypertension A cornerstone of primary care: Lowering high blood pressure prevents cardiovascular
Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular
Mayo Clinic 90 th Annual Clinical Reviews November 2 nd and 16 th, 2016 Hypertension Update Vincent J. Canzanello, M.D. Consultant, Division of Nephrology and Hypertension Professor or Medicine College
Update on CVD and Microvascular Complications in T2D Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine
The Failing Heart in Primary Care Hamid Ikram How fares the Heart Failure Epidemic? 4357 patients, 57% women, mean age 74 years HFSA 2010 Practice Guideline (3.1) Heart Failure Prevention A careful and
Hypertension diagnosis (see detail document) Non-diabetic Diabetic Very elderly (older than 80 years) Target less than 140/90mmHg Target less than 130/80mmHg Consider SBP target less than 150mmHg Non-diabetic
Which antihypertensives are more effective in reducing diastolic hypertension versus systolic hypertension? May 24, 2017 The most important reason for treating hypertension in primary care is to prevent
Management of Hypertension in special groups BY DR-Mohammed Salah Assistant Lecturer of Cardiology Mansoura University AGENDA SPECIAL GROUPS SPECIFIC DRUDS FOR SPECIAL GROUPS TARGET BP FOR SPECIAL GROUPS: